+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 75Years
All Genders
ID06574568

Phase I Study to Assess Safety, Tolerability, and Effectiveness of YKST02 in Adults with Relapsed or Refractory Multiple Myeloma

Led by Excyte Biopharma Ltd · Updated on 2026-02-05

70

Participants Needed

12

Research Sites

25 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating YKST02, a new medicine designed to activate the bodys immune system to fight relapsed or refractory multiple myeloma, a cancer of plasma cells in the blood. This first-in-human study aims to assess the safety, tolerability, how the body processes the medicine, and its initial effectiveness in patients who have already undergone prior treatments. The study is sponsored by Excyte Biopharma Ltd and includes patients aged 18 to 75 years with measurable disease and prior therapies.

CONDITIONS

Brief Title

A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma

Research Team

W

Wenming Chen, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here